Our top pick for
OpGen Inc is a diagnostics & research business based in the US. OpGen shares (OPGN) are listed on the NASDAQ and all prices are listed in US Dollars. OpGen employs 94 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.89|
|52-week range||$1.63 - $4.05|
|50-day moving average||$2.89|
|200-day moving average||$2.49|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.36|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-6.90%|
|1 month (2021-09-24)||-38.03%|
|3 months (2021-07-23)||-15.25%|
|6 months (2021-04-23)||-12.90%|
|1 year (2020-10-23)||-23.48%|
|2 years (2019-10-24)||15.24%|
|3 years (2018-10-24)||47.66%|
|5 years (2016-10-24)||7.39%|
|Revenue TTM||$4.1 million|
|Gross profit TTM||$-9,598,770|
|Return on assets TTM||-26.59%|
|Return on equity TTM||-125.63%|
|Market capitalisation||$77.7 million|
TTM: trailing 12 months
There are currently 763,298 OpGen shares held short by investors – that's known as OpGen's "short interest". This figure is 29.6% up from 588,930 last month.
There are a few different ways that this level of interest in shorting OpGen shares can be evaluated.
OpGen's "short interest ratio" (SIR) is the quantity of OpGen shares currently shorted divided by the average quantity of OpGen shares traded daily (recently around 1.6 million). OpGen's SIR currently stands at 0.47. In other words for every 100,000 OpGen shares traded daily on the market, roughly 470 shares are currently held short.
However OpGen's short interest can also be evaluated against the total number of OpGen shares, or, against the total number of tradable OpGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OpGen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 OpGen shares in existence, roughly 20 shares are currently held short) or 0.0212% of the tradable shares (for every 100,000 tradable OpGen shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OpGen.
Find out more about how you can short OpGen stock.
We're not expecting OpGen to pay a dividend over the next 12 months.
OpGen's shares were split on a 1:20 basis on 28 August 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OpGen shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OpGen shares which in turn could have impacted OpGen's share price.
Over the last 12 months, OpGen's shares have ranged in value from as little as $1.63 up to $4.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OpGen's is -0.5063. This would suggest that OpGen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, OpGen has bucked the trend.
OpGen, Inc. , a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.